These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 11841360)
1. Pharmacogenetics in clinical dermatology. Ameen M; Smith CH; Barker JN Br J Dermatol; 2002 Jan; 146(1):2-6. PubMed ID: 11841360 [TBL] [Abstract][Full Text] [Related]
2. Role of dermatology in pharmacogenomics: drug-induced skin injury. Borroni RG Pharmacogenomics; 2015; 16(4):401-12. PubMed ID: 25823788 [TBL] [Abstract][Full Text] [Related]
3. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Rufini S; Ciccacci C; Politi C; Giardina E; Novelli G; Borgiani P Pharmacogenomics; 2015 Nov; 16(17):1989-2002. PubMed ID: 26555663 [TBL] [Abstract][Full Text] [Related]
4. New advances in pharmacogenomics. Destenaves B; Thomas F Curr Opin Chem Biol; 2000 Aug; 4(4):440-4. PubMed ID: 10959773 [TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetics and prediction of side effects of drugs]. Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798 [TBL] [Abstract][Full Text] [Related]
6. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs. Zhang Z; Wu Y; Tan NC; Jiang Y Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464 [TBL] [Abstract][Full Text] [Related]
7. [State of the art of pharmacogenetic diagnostics in drug therapy]. Kirchheiner J; Seeringer A; Brockmöller J Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776 [TBL] [Abstract][Full Text] [Related]
8. An update on the pharmacogenetics of treating hypertension. Fontana V; Luizon MR; Sandrim VC J Hum Hypertens; 2015 May; 29(5):283-91. PubMed ID: 25355012 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Pincelli C; Pignatti M; Borroni RG Exp Dermatol; 2009 Apr; 18(4):337-49. PubMed ID: 19348000 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. Jaramillo NM; Galindo IF; Vázquez AO; Cook HJ; LLerena A; López ML Drug Metabol Drug Interact; 2014; 29(2):67-79. PubMed ID: 24406279 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy. Udagawa C; Zembutsu H Cancer Sci; 2020 Oct; 111(10):3445-3457. PubMed ID: 32780457 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Shah RR Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578 [TBL] [Abstract][Full Text] [Related]
14. Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Johnson JA; Evans WE Trends Mol Med; 2002 Jun; 8(6):300-5. PubMed ID: 12067617 [TBL] [Abstract][Full Text] [Related]
15. How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. Dalle S; Thomas L; Shear NH Int J Dermatol; 2011 Jan; 50(1):114-8. PubMed ID: 21182511 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of Adverse Drug Reactions. Osanlou O; Pirmohamed M; Daly AK Adv Pharmacol; 2018; 83():155-190. PubMed ID: 29801574 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic application in drug development and clinical trials. Shi MM; Bleavins MR; de la Iglesia FA Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):591-5. PubMed ID: 11259358 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and adverse drug reactions. Meyer UA Lancet; 2000 Nov; 356(9242):1667-71. PubMed ID: 11089838 [TBL] [Abstract][Full Text] [Related]